文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治愈丙型肝炎病毒感染后代谢功能障碍相关脂肪性肝病患者新发肝细胞癌的风险

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
PubMed 文献 · J Hepatol · 2024-10-03

本研究在台湾纳入1,598例经直接抗病毒药物(DAA)治疗获得持续病毒学应答(SVR12)的丙型肝炎患者,每半年进行甲胎蛋白和肝脏影像学监测以发现新发肝细胞癌(HCC)。代谢功能障碍相关脂肪性肝病(MASLD)定义为受控衰减参数(CAP)≥248 dB/m且至少1项心血管代谢危险因素(CMRF)。MASLD患者累积HCC发生率高于无MASLD者(log-rank检验 p<0.001)。多变量Cox回归显示MASLD与HCC独立相关(校正风险比2.07;95%CI 1.36-3.16;p<0.001),Fine-Gray模型证实(亚分布风险比2.07;95%CI 1.34-3.19;p<0.001)。MASLD显著介导了CMRF对HCC发生的影响。

要点

  • DAA治愈HCV后,MASLD患者新发HCC风险约为无MASLD者的2倍(校正HR 2.07)。
  • MASLD显著介导心血管代谢危险因素对HCC发生的影响。
  • 该人群需警惕HCC监测并控制心血管代谢危险因素。

核心结论

  • 获得SVR12后,MASLD患者较无MASLD者HCC风险增高。
  • 对该人群,警惕性HCC监测和控制CMRF以减轻MASLD对HCC的影响仍然至关重要。

研究设计与样本

  • 共纳入1,598例符合条件的患者,在获得SVR12后每半年接受甲胎蛋白和肝脏影像学监测以发现新发HCC。

主要发现

  • HCC发病率为每100人年随访1.44例(95%CI 1.19-1.74)。
  • MASLD患者累积HCC发生率高于无MASLD者(log-rank检验 p<0.001)。
  • 多变量Cox回归显示,除年龄、性别、肝硬度测量、血小板计数和甲胎蛋白外,MASLD与HCC独立相关(校正风险比2.07;95%CI 1.36-3.16;p<0.001)。
  • Fine-Gray模型显示MASLD的亚分布风险比为2.07(95%CI 1.34-3.19,p<0.001)。
  • MASLD显著介导了CMRF对HCC发生的影响。

关键数值与推荐

  • MASLD定义为CAP≥248 dB/m且≥1项CMRF。
  • SVR12定义为停治疗第12周持续病毒学应答。

临床怎么用

  • 作者认为,对该人群警惕性HCC监测和控制CMRF以减轻MASLD对HCC的影响仍然至关重要。
  • 作者认为,药物干预和积极生活方式调整以控制MASLD患者的心血管代谢危险因素至关重要,并需警惕性HCC监测以确保HCV根除后的良好结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Data are limited on the risk of de novo hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who have achieved sustained virologic response at off-treatment week 12 (SVR12) using direct-acting antivirals (DAAs) for HCV. METHODS: A total of 1,598 eligible patients received biannual alpha-fetoprotein (AFP) and liver imaging surveillance to detect de novo HCC after achieving SVR12. MASLD was defined as presence of controlled attenuation parameter (CAP) ≥248 dB/m and ≥1 cardiometabolic risk factor (CMRF). Cumulative HCC incidence was compared between patients with/without MASLD. We built univariable and multivariable Cox proportional hazards models to evaluate factors associated with HCC. Sensitivity analysis was performed using the Fine-Gray subdistribution hazards model. Additionally, we evaluated the mediation effect of MASLD on CMRFs and of CMRFs on MASLD for HCC using mediation analysis with bootstrapping. RESULTS: The incidence rate of HCC was 1.44 per 100 person-years of follow-up (95% CI 1.19-1.74). Patients with MASLD had a higher cumulative HCC incidence than those without MASLD (log-rank test, p <0.001). Multivariable Cox regression analysis revealed that in addition to age, sex, liver stiffness measurement, platelet count, and AFP, MASLD (adjusted hazard ratio 2.07; 95% CI 1.36-3.16; p <0.001) was independently associated with HCC. This finding was confirmed by the Fine-Gray model, which showed a subdistribution hazard ratio of 2.07 (95% CI 1.34-3.19, p <0.001) for MASLD. MASLD significantly mediated CMRFs for HCC development. CONCLUSION: After achieving SVR12, patients with MASLD exhibited an increased HCC risk compared to those without MASLD. Vigilant HCC surveillance and control of CMRFs to mitigate the effect of MASLD on HCC remain crucial for this population. IMPACT AND IMPLICATIONS: The risk of de novo hepatocellular carcinoma (HCC) among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who have attained a sustained virologic response to direct-acting antivirals remains to be confirmed. In this study, recruiting 1,598 patients in Taiwan, individuals with MASLD had an approximately two-fold increased risk of de novo HCC compared to those without MASLD after achieving a sustained virologic response. MASLD significantly mediated cardiometabolic risk factors for HCC development. Our findings underscore the critical importance of pharmacological interventions and proactive lifestyle modifications to control cardiometabolic risk factors in patients with MASLD, as well as the need for vigilant HCC surveillance to ensure favorable outcomes following HCV eradication.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu CH, Cheng PN, Fang YJ, et al. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. J Hepatol. 2024. PMID: 39368711. doi:10.1016/j.jhep.2024.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。